Jan 11, 2021
Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases. In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.
@abpro #COVID19 #antibodytherapies #monoclonalantibodies